Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

20061,195 citationsJournal Articlebronze Open Access

Authors

Ghassan K. Abou‐Alfa · Tel Aviv Sourasky Medical Center

Lawrence H. Schwartz · Tel Aviv Sourasky Medical Center

Sergio Ricci · Memorial Sloan Kettering Cancer Center

Dino Amadori · Memorial Sloan Kettering Cancer Center

Armando Santoro · Tel Aviv Sourasky Medical Center

Arié Figer · Tel Aviv Sourasky Medical Center

Jacques De Grève

Abstract

Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy Liver physiology and pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 24, Issue 26, pp. 4293-4300

DOI: 10.1200/jco.2005.01.3441

Field-Weighted Citation Impact: 50.93